Treatment of isolated growth hormone deficiency type IA due to GH-I gene deletion with recombinant human insulin-like growth factor I.
Biosynthetic insulin-like growth factor I (IGF-I) was administered subcutaneously twice a day for one year to a patient with isolated growth hormone deficiency (IGHD) type IA with high titres of anti-GH antibody (up to 1:1,000,000). During IGF-I therapy he showed good linear growth without any side effects, such as hypoglycemia and anti-IGF-I antibody formation. Administration of IGF-I to IGHD type IA with poor response to GH therapy appears to have a beneficial effect on growth.